千金药业
(600479)
| 流通市值：51.64亿 | | | 总市值：60.74亿 |
| 流通股本：4.19亿 | | | 总股本：4.92亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,918,299,373.44 | 970,265,534.34 | 3,628,843,106.61 | 2,718,335,546.6 |
| 营业收入 | 1,918,299,373.44 | 970,265,534.34 | 3,628,843,106.61 | 2,718,335,546.6 |
| 二、营业总成本 | 1,706,645,826.09 | 883,983,897.86 | 3,248,878,976.3 | 2,458,728,936.98 |
| 营业成本 | 965,287,841.18 | 495,553,589.22 | 1,858,832,653.58 | 1,362,590,676.64 |
| 税金及附加 | 20,609,950.01 | 9,490,826.77 | 40,945,051.55 | 30,606,071.88 |
| 销售费用 | 483,293,269.12 | 269,910,365.27 | 875,029,294.97 | 721,941,833.62 |
| 管理费用 | 145,497,713.58 | 68,488,783.26 | 306,055,030.15 | 212,501,698.23 |
| 研发费用 | 90,227,593.02 | 38,971,545.75 | 185,600,017.47 | 144,903,869.25 |
| 财务费用 | 1,729,459.18 | 1,568,787.59 | -17,583,071.42 | -13,815,212.64 |
| 其中:利息费用 | - | - | 52,966.67 | 48,833.34 |
| 其中:利息收入 | 150,303.4 | 301,932.9 | 23,304,730.3 | 18,259,633.5 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -864,129.02 | 283,598.66 | 2,407,585.49 | 1,539,015.05 |
| 加:投资收益 | 13,658,049.61 | 10,876,693.16 | 44,191,162.06 | 42,442,567.56 |
| 资产处置收益 | 706,539.26 | 168,864.47 | 1,875,639.98 | 1,457,271.84 |
| 资产减值损失(新) | -27,178.14 | 260,017.03 | -4,067,560.71 | -668,324.6 |
| 信用减值损失(新) | -6,067,506.31 | -9,753,154.9 | -2,492,378.46 | -12,209,952.8 |
| 其他收益 | 15,063,261.13 | 9,282,850.65 | 15,373,169.71 | 8,420,964.98 |
| 四、营业利润 | 234,122,583.88 | 97,400,505.55 | 437,251,748.38 | 300,588,151.65 |
| 加:营业外收入 | 661,727.67 | 368,057.7 | 1,244,274.61 | 493,359.52 |
| 减:营业外支出 | 2,192,154.12 | 1,211,874.62 | 3,394,343.21 | 2,369,147.5 |
| 五、利润总额 | 232,592,157.43 | 96,556,688.63 | 435,101,679.78 | 298,712,363.67 |
| 减:所得税费用 | 32,692,486.16 | 12,364,748.05 | 59,430,879.02 | 40,479,493.43 |
| 六、净利润 | 199,899,671.27 | 84,191,940.58 | 375,670,800.76 | 258,232,870.24 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 199,899,671.27 | 84,191,940.58 | 375,670,800.76 | 258,232,870.24 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 180,846,237.17 | 75,003,617.18 | 286,293,094.19 | 187,355,173.74 |
| 少数股东损益 | 19,053,434.1 | 9,188,323.4 | 89,377,706.57 | 70,877,696.5 |
| 扣除非经常损益后的净利润 | 176,125,257.42 | 72,330,449.94 | 279,393,713.73 | 169,638,123.2 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.37 | 0.15 | 0.66 | 0.45 |
| (二)稀释每股收益 | 0.37 | 0.15 | 0.66 | 0.45 |
| 八、其他综合收益 | 579.95 | -458.94 | 183,896.35 | 524,130.45 |
| 归属于母公司股东的其他综合收益 | 579.95 | -458.94 | 183,896.35 | 524,130.45 |
| 九、综合收益总额 | 199,900,251.22 | 84,191,481.64 | 375,854,697.11 | 258,757,000.69 |
| 归属于母公司股东的综合收益总额 | 180,846,817.12 | 75,003,158.24 | 286,476,990.54 | 187,879,304.19 |
| 归属于少数股东的综合收益总额 | 19,053,434.1 | 9,188,323.4 | 89,377,706.57 | 70,877,696.5 |
| 公告日期 | 2026-08-26 | 2026-04-29 | 2026-04-29 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |